Eslicarbazepine acetate in partial-onset seizures A time-based analysis

Lattanzi S, Cagnetti C, Foschi N, Lorusso A, Provinciali L, Silvestrini M Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Italy

Aim: The study aim was to evaluate the clinical response to eslicarbazepine acetate (ESL) as add-on therapy in adult patients with partial-onset seizures through a time-based approach.^{1,2}


Materials and methods: Consecutive patients presenting with partial onset seizures, with or without secondary generalization, prescribed to add-on ESL were identified. Seizure occurrence, treatment compliance and drug toxicity were assessed at baseline and every follow-up visits. The time-to-baseline monthly seizure count was the main study outcome. The rate of treatment-related adverse events (AEs) was the secondary endpoint.

Independent Variable	Multivariate Analysis HR (95% CI)
Type of seizure	0.88 (0.53-1.47)
Duration of epilepsy	1.00 (0.99-1.02)
Concomitant AEDs One	
Two	2.22 (1.18-4.14)
Three or more	3.65 (1.66-8.06)
Baseline seizure count	0.99 (0.98-1.01)

Results: The median time-tobaseline monthly seizure count was 46 (35-101) days in the overall study cohort. The number of concomitant antiepileptic drugs was inversely related to the timeto-endpoint.

There were no differences in the main study outcome according to prior versus

0



never exposure to CBZ/OXC. AEs occurred in 53.4% of patients; the most frequently dizziness reported were (13.6%), somnolence (11.9%), nausea (6.8%) and fatigue (5.1%).

Conclusions

Add-on ESL was effective and well tolerated overall in adults patients with partial onset seizures.

References

- 1. Zelano J, Ben-Menachem E. Eslicarbazepine acetate for the treatment of partial epilepsy. Expert Opin Pharmacother. 2016;17:1165-1169.
- 2. Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology 2015;89:122-135.